Akari Therapeutics (AKTX) Interest Expenses (2014 - 2026)
Akari Therapeutics recorded quarterly Interest Expenses of $61000.0 in Q1 2026, down 92.82% quarter-over-quarter from $849000.0 in Q4 2025, and up 10.91% year-over-year from $55000.0 in Q1 2025.
Akari Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $61000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 10.91% year-over-year to $61000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 96.16% YoY), while the FY2025 annual figure was $949000.0, up 31533.33% from the prior year.
- Interest Expenses came in at $61000.0 for Q1 2026 at Akari Therapeutics, down from $849000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $28.0 million in Q4 2024 to a low of $50000.0 in Q2 2025.
- A 3-year average of $3.7 million and a median of $65000.0 in 2024 frame the typical range for Interest Expenses.
- On a YoY basis, Interest Expenses climbed as much as 75.36% in 2025 and fell as far as 96.97% in 2025.
- Akari Therapeutics' Interest Expenses stood at $28.0 million in 2024, then plunged by 96.97% to $849000.0 in 2025, then plunged by 92.82% to $61000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $61000.0, $849000.0, and $121000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 12.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,000.00 |
| Mar 31, 2026 | 61,000.00 |
| Dec 31, 2025 | 723,000.00 |
| Dec 31, 2025 | 723,000.00 |
| Sep 30, 2025 | 121,000.00 |
| Sep 30, 2025 | 121,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Jun 30, 2025 | 50,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Mar 31, 2025 | 55,000.00 |
| Dec 31, 2024 | 28.01 Mn |
| Dec 31, 2024 | 28.01 Mn |
| Sep 30, 2024 | 69,000.00 |
| Sep 30, 2024 | 69,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Jun 30, 2024 | 51,000.00 |
| Dec 31, 2015 | 6.11 Mn |
| Dec 31, 2015 | 6.11 Mn |
| Sep 30, 2015 | -3.05 Mn |
| Sep 30, 2015 | -3.05 Mn |
| Jun 30, 2015 | -2,613.00 |
| Jun 30, 2015 | -2,613.00 |
| Mar 31, 2015 | 4,556.00 |
| Mar 31, 2015 | 4,556.00 |
| Dec 31, 2014 | -2,111.00 |
| Dec 31, 2014 | -2,111.00 |
| Sep 30, 2014 | 2,882.00 |
| Sep 30, 2014 | 2,882.00 |